CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.
Similar Posts
Interview With James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature James Hallifax, Co-Founder of The Psychedelic Investor.
Interview With Nick Levich
Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.
Interview With Dustin Robinson
Mr. Psychedelic Law’s Co-Founding Partner, Dustin Robinson, talks about how he became involved with the medicinal psychedelic space.
Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
Spotlight on Cannara Biotech with Nicholas Sosiak
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company’s future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund
This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.